Docetaxel (D) Plus Prednisone (P) in Combination with Metronomic Cyclophosphamide (CTX) and Celecoxib (C) as First Line Treatment in Metastatic Hormone Refractory Prostate Cancer (MHRPC): a Phase II Clinical Trial with Pharmacodynamic Evaluation